TrialClinical cancer research : an official journal of the American Association for Cancer Research2017

Exposure-Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies.

Shailly Mehrotra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.